AJANTPHARM: Strong FY 2026 growth with high teens revenue and 27% EBITDA margin guided for FY 2027
AJANTPHARM: Strong FY 2026 growth with high teens revenue and 27% EBITDA margin guided for FY 2027
AJANTPHARM: Strong FY 2026 growth with high teens revenue and 27% EBITDA margin guided for FY 2027
Sector
BROAD_MARKET
News Type
MARKET
Impact Level
MEDIUM
AI Sentiment
POSITIVE
Published
11 May 2026
📎 Sources
Quartr | https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3309794:0-ajantpharm-strong-fy-2026-growth-with-high-teens-revenue-and-27-ebitda-margin-guided-for-fy-2027/